TuHURA Biosciences (HURA) Income towards Parent Company (2010 - 2012)
TuHURA Biosciences' (HURA) quarterly Income towards Parent Company came in at -$7405.0 in Q4 2012, up 62.24% year-on-year from -$4564.2 in Q1 2012, and down 78.22% quarter-over-quarter from -$4155.0 in Q3 2012.
TuHURA Biosciences (HURA) Income towards Parent Company (2010 - 2012) Analysis & Trends
TuHURA Biosciences' Income towards Parent Company history runs 3 years deep, the most recent figure standing at -$7405.0 for Q4 2012.
- On a quarterly basis, Income towards Parent Company rose 62.24% year-over-year to -$7405.0 in Q4 2012; TTM through Sep 2013 was -$7405.0, a 85.76% increase from a year earlier, with the FY2012 full-year figure at -$18885.0, up 43.01% from the prior year.
- Income towards Parent Company eased to -$7405.0 in Q4 2012 per HURA's latest filing, from -$4155.0 in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$3858.0 in Q3 2011 and bottomed at -$23526.0 in Q1 2012.
- The 3-year median for Income towards Parent Company is -$7118.0 (2011), against an average of -$10584.6.
- Across the five-year window, Income towards Parent Company sank 34.62% in 2011 and surged 62.24% in 2012, its largest moves.
- Year by year, Income towards Parent Company stood at -$14568.0 in 2010, then sank by 34.62% to -$19612.0 in 2011, then jumped by 62.24% to -$7405.0 in 2012.
- Per Business Quant, the three latest HURA Income towards Parent Company figures stand at -$7405.0 (Q4 2012), -$4155.0 (Q3 2012), and -$4722.0 (Q2 2012).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | TuHURA Biosciences | 132.62 Mn | 132.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -7,405.00 |
| Sep 30, 2012 | -4,155.00 |
| Jun 30, 2012 | -4,722.00 |
| Mar 31, 2012 | -23,526.00 |
| Dec 31, 2011 | -19,612.00 |
| Sep 30, 2011 | -3,858.00 |
| Jun 30, 2011 | -6,831.00 |
| Dec 31, 2010 | -14,568.00 |